Poulton Stuart 4

What Happened Stuart Poulton, EVP & Chief Development Officer of Karyopharm Therapeutics (KPTI), disposed of 378 shares in an S-class sale on 2026-02-17. The shares were sold at $8.63 each for a total of $3,262. This sale was a broker-assisted transaction to cover withholding taxes on vested restricted stock units and was not a discretionary trade by the insider.

Key Details

• Transaction date and price: 2026-02-17 — 378 shares at $8.63 per share (total $3,262).
• Transaction type: Sale (S) — open market / broker-assisted sale to satisfy tax withholding.
• Footnote: Transaction executed under a durable automatic sale instruction plan adopted May 18, 2022; sale was to cover RSU tax withholding and not a discretionary trade (F1).
• Filing/Timeliness: Report covers 2026-02-17 and was filed with the SEC on 2026-02-19 — appears timely.
• Shares owned after transaction: Not specified in the information provided in this summary.

Context This was a routine, tax-related broker-assisted sale of vested RSUs rather than a voluntary market-timed sale. Such transactions are common for executives to satisfy tax withholding obligations and do not by themselves indicate insider sentiment about the company’s outlook.